5Needham Reiterates Buy on Cogent Biosciences, Maintains $18 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Ami Fadia reiterates a Buy rating on Cogent Biosciences (NASDAQ:COGT) and maintains a price target of $18.
August 07, 2024 | 11:13 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Needham analyst Ami Fadia reiterates a Buy rating on Cogent Biosciences and maintains a price target of $18.
The reiteration of a Buy rating and the maintenance of a price target at $18 by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100